Skip to main content

Table 2 Non-hematologic toxicity

From: A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer

 

Grade of toxicity (NCI-CTVAE grade v2.0)

1

2

3

4

n(%)

n(%)

n(%)

n(%)

Arthralgia

23(31)

2(3)

1(1)

0(0)

Myalgia

29(39)

4(5)

0(0)

0(0)

Nausea

36(49)

12(16)

4(5)

0(0)

Vomiting

9(12)

7(9)

4(5)

0(0)

Mucositis/Stomatitis

21(28)

13(18)

0(0)

0(0)

Neurohearing

3(4)

1(1)

0(0)

0(0)

Neuromotor

2(3)

1(1)

0(0)

0(0)

Neurosensory

34(46)

4(5)

1(1)

0(0)

Edema

13(18)

4(5)

0(0)

0(0)

Fatigue

24(32)

18(24)

0(0)

0(0)

Change of taste

13(18)

4(5)

0(0)

0(0)

Anorexia/weight loss

2(3)

1(1)

0(0)

0(0)

Diarhoe

6(8)

0(0)

0(0)

0(0)

Nail changes

6(8)

5(7)

0(0)

0(0)

Rash

2(3)

1(1)

0(0)

0(0)

Epiphora

1(1)

2(3)

0(0)

0(0)

  1. NCI-CTCAE: National Cancer Institute Common Toxicity Criteria for Adverse Events.